

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

Docket No. : 37164/MAH/U33

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled **USE OF METHYLNALTREXONE AND RELATED COMPOUNDS TO TREAT CHRONIC OPIOID USE SIDE EFFECTS**, the specification of which is attached hereto unless the following is checked:

— was filed on __ as United States Application Number or PCT International Application Number __ and was amended on __ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of the foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

<u>Application Number</u>	<u>Country</u>	<u>Filing Date (day/month/year)</u>	<u>Priority Claimed</u>
---------------------------	----------------	-------------------------------------	-------------------------

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below.

<u>Application Number</u>	<u>Filing Date</u>
---------------------------	--------------------

60/168,480	December 1, 1999
------------	------------------

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

<u>Application Number</u>	<u>Filing Date</u>	<u>Patented/Pending/Abandoned</u>
09/120,703	July 22, 1998	Pending
08/962,742	November 3, 1997	Patented (5,972,954)

**DECLARATION AND POWER OF ATTORNEY
FOR PATENT APPLICATIONS**

Docket No. 37164/MAH/U33


POWER OF ATTORNEY: I hereby appoint the following attorneys and agents of the law firm CHRISTIE, PARKER & HALE, LLP to prosecute this application and any international application under the Patent Cooperation Treaty based on it and to transact all business in the U.S. Patent and Trademark Office connected with either of them in accordance with instructions from the assignee of the entire interest in this application; or from the first or sole inventor named below in the event the application is not assigned; or from _____ in the event the power granted herein is for an application filed on behalf of a foreign attorney or agent.


R. W. Johnston	(17,968)	Grant T. Langton	(39,739)	Jun-Young E. Jeon	(43,693)
D. Bruce Prout	(20,958)	Constantine Marantidis	(39,759)	Marc A. Karish	(44,816)
Hayden A. Carney	(22,653)	Daniel R. Kimbell	(34,849)	John F. O'Rourke	(38,985)
Richard J. Ward, Jr.	(24,187)	Craig A. Gelfound	(41,032)	Richard J. Paciulan	(28,248)
Russell R. Palmer, Jr.	(22,994)	Syed A. Hasan	(41,057)	Josephine E. Chang	(46,083)
LeRoy T. Rahn	(20,356)	Kathleen M. Olster	(42,052)	Frank L. Cire	(42,419)
Richard D. Seibel	(22,134)	Daniel M. Cavanagh	(41,661)	Harold E. Wurst	(22,183)
Walter G. Maxwell	(25,355)	Molly A. Holman	(40,022)	Robert A. Green	(28,301)
William P. Christie	(29,371)	Lucinda G. Auciello	(42,270)	Derrick W. Reed	(40,138)
David A. Dillard	(30,831)	Norman E. Carte	(30,455)	John W. Peck	(44,284)
Thomas J. Daly	(32,213)	Joel A. Kauth	(41,886)	Stephen D. Burbach	(40,285)
Vincent G. Gioia	(19,959)	Patrick Y. Ikehara	(42,681)	David B. Sandelands, Jr.	(46,023)
Edward R. Schwartz	(31,135)	Mark Garscia	(31,953)	Heidi L. Eisenhut	(P-46,812)
John D. Carpenter	(34,133)	Gary J. Nelson	(44,257)	Nicholas J. Pauley	(44,999)
David A. Plumley	(37,208)	Raymond R. Tabandeh	(43,945)	Mark J. Marcelli	(36,593)
Wesley W. Monroe	(39,778)	Phuong-Quan Hoang	(41,839)		
Gregory S. Lampert	(35,581)	Cynthia A. Bonner	(44,548)		

The authority under this Power of Attorney of each person named above shall automatically terminate and be revoked upon such person ceasing to be a member or associate of or of counsel to that law firm.

DIRECT TELEPHONE CALLS TO : Molly A. Holman, Ph.D., 626/795-9900
SEND CORRESPONDENCE TO : CHRISTIE, PARKER & HALE, LLP
 P.O. Box 7068, Pasadena, CA 91109-7068


I declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.


Full name of sole or first joint inventor Joseph F. Foss	Inventor's signature 	Date 8 Sep 2000
Residence and Post Office Address 4338 North Clarendon, Apt. 3, Chicago, Illinois 60613		Citizenship USA

Full name of second joint inventor Michael F. Roizen	Inventor's signature 	Date 9/7/2000
Residence and Post Office Address 5622 South Woodlawn Avenue, Chicago, Illinois 60637		Citizenship USA

DECLARATION AND POWER OF ATTORNEY
FOR PATENT APPLICATIONS

Docket No. 37164/MAH/U33

Full name of third joint inventor Jonathan Moss	Inventor's signature 	Date 9/7/00
Residence and Post Office Address 5827 South Blackstone, Chicago, Illinois 60637		Citizenship USA

Full name of fourth joint inventor Chun-Su Yuan	Inventor's signature 	Date 9/7/00
Residence and Post Office Address 940 East 55th Street, Chicago, Illinois 60615		Citizenship China

Full name of fifth joint inventor William Drell	Inventor's signature	Date
Residence and Post Office Address 4566 Sherlock Court, San Diego, California 92122		Citizenship USA

LLW PAS270044.1-8/25/00 3:44 PM

DECLARATION AND POWER OF ATTOR Y
FOR PATENT APPLICATIONS

Docket No. 87164/MAH/U33

Full name of third joint inventor Jonathan Moss	Inventor's signature	Date
Residence and Post Office Address 5827 South Blackstone, Chicago, Illinois 60637	Citizenship USA	

Full name of fourth joint inventor Chun-Su Yuan	Inventor's signature	Date
Residence and Post Office Address 940 East 55th Street, Chicago, Illinois 60615	Citizenship China	

Full name of fifth joint inventor William Drell	Inventor's signature <i>William Drell</i>	Date 9/20/00
Residence and Post Office Address 4566 Sherlock Court, San Diego, California 92122	Citizenship USA	

LLW PAS270044.1--8/25/00 1:49 PM

P0453.70113US04
Express Mail Label No.:
EL 926059820 US
Date of Deposit: February 24, 2004

ATTORNEY'S DOCKET NO: P0453/9020 (ERG/CSM)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
Washington, D.C. 20231

REVOCATION OF POWER OF ATTORNEY BY ASSIGNEE
AND
NEW POWER OF ATTORNEY

Sir:

The undersigned, UR Labs, Inc. and The University of Chicago, the assignees of the entire right, title and interest in patent application identified below, hereby revoke all previous powers of attorney or authorizations of agent given in the following application:

U.S. 09/669,358

and in any divisional, continuing, substitute, renewal or reissue applications thereof, and appoint all practitioners affiliated with Customer Number:



23628

as assignees' attorneys or agents with full power of substitution to take any and all action necessary with regard to the identified patents and patent applications, and with regard to any divisional, continuing, substitute, renewal or reissue applications thereof. Please address all telephone calls to Edward R. Gates, Esq., at telephone number: (617) 720-3500.

Address all correspondence to:

Edward R. Gates, Esq.
c/o Wolf, Greenfield & Sacks, P.C.,
Federal Reserve Plaza
600 Atlantic Avenue
Boston, MA 02210-2211

By:

Eliot Drell
President, UR Labs, Inc.

By:

Name: Alan Thorpe
Title: Director, Technology Commercialization
The University of Chicago

377671.2

CERTIFICATE UNDER 37 CFR 3.73(b)

Applicant:	J. Foss et al.	
Application No.:	09/669,358	Filed: September 26, 2000
Entitled:	USE OF METHYLNALTREXONE AND RELATED COMPOUNDS TO TREAT CHRONIC OPIOID USE SIDE EFFECTS	

The University of Chicago, an Illinois University, and U.R. Labs, a Nevada Corporation, certify that together they are the assignees of the entire right, title, and interest, in the patent application identified above by virtue of assignments from the inventors of the patent application identified above. The assignments were recorded in the Patent and Trademark Office at Reel 011184, Frame 0864, and Reel 011184, Frame 0871.

A copy of an agreement between the University of Chicago and Arch Development Corporation showing the chain of title is enclosed.

The undersigned are empowered to sign this certificate on behalf of the assignees.

11/28/00
Date


Name: ALAN BURNS
Title: Manager, Technology Commercialization
The University of Chicago

Date

Eliot Drell
President, U.R. Labs, Inc.

CERTIFICATE UNDER 37 CFR 1.73(b)

Applicant: J. Fass et al.

Application No.:

09/669,358

Filed: September 26, 2000

Emitted:

USE OF METHYLNALTREXONE AND RELATED COMPOUNDS TO
CHRONIC OPIOID USE SIDE EFFECTS

The University of Chicago, an Illinois University, and U.R. Labs, a Nevada Corporation, certify that they are the assignees of the entire right, title, and interest, in the patent application identified above by assignments from the inventors of the patent application identified above. The assignments were recorded in the Patent and Trademark Office at Reel 011184, Frame 0864, and Reel 011184, Frame 0871.

A copy of an agreement between the University of Chicago and Arch Development Corporation above chain of title is enclosed.

The undersigned are empowered to sign this certificate on behalf of the assignees.

Date

12/5/01

Date

Name:

Title:

The University of Chicago

Eliot DrellEliot Drell
President, U.R. Labs, Inc.

AGREEMENT BETWEEN
THE UNIVERSITY OF CHICAGO
AND
ARCH DEVELOPMENT CORPORATION

The University of Chicago (the "University") and ARCH Development Corporation ("ARCH") enter into this agreement as of July 1, 2001.

In 1985 the University arranged for the incorporation of ARCH as an Illinois not-for-profit corporation to perform technology transfer services for the University and Argonne National Laboratory ("Argonne"). On July 1, 1987, the University and ARCH entered into an agreement to carry out this purpose. Since then ARCH successfully engaged in the business of technology transfer for the University and Argonne. It issued numerous licenses of technology, applied for patents on inventions, copyrighted software and other works, assisted in the start-up of corporations and performed other activities in furtherance of its mission. The University has now established an office within the University called UCTECH to manage technology transfer and to take over the responsibility for such activity from ARCH. The parties enter into this agreement to arrange for a smooth transition of the conduct of technology transfer from ARCH to the University.

Accordingly, the parties agree as follows:

1. The existing patents and other intellectual property owned by ARCH will continue to be held in the name of ARCH until further action of the parties. By written notice, the University may direct ARCH to assign to transfer to it any invention, patent application, patent or other intellectual property owned by ARCH, and, in such event, the parties will cooperate in issuing and executing the necessary documents to effect such assignment or transfer.
2. The University, acting through UCTECH, will carry out all licensing and other actions required for the transfer of technology, either in the name of the University or of ARCH. Persons dealing with the University may be assured that it has full authority to act in the name of ARCH. This means the University may license or assign patents or other intellectual property owned by ARCH, or cause such actions to take place.
3. ARCH hereby designates the University to act as its agent in all dealings respecting its inventions, patents, patent applications, software, copyrighted materials and other intellectual property, licenses, contracts and other business dealings with any and all persons and governmental authorities.
4. The Agreement of July 1, 1987 is terminated as of July 1, 2001.

5. This agreement may be amended by written agreement of the parties.

IN WITNESS WHEREOF, the parties have signed this agreement as of the date first set forth above.

THE UNIVERSITY OF CHICAGO

BY

ITS Vice President

ARCH DEVELOPMENT CORPORATION

BY

ITS Vice President